FACS-based dual fluorescence reporter assay demonstrates efficacy of antisense oligonucleotide therapy of novel PRPF3 intronic splice variant

Vadim Dolgin, Ekaterina Eremenko, Ginat Narkis, Masha Mazor-Oring, Libe Gradstein, Ohad S. Birk · 2026

Read FACS-based dual fluorescence reporter assay demonstrates efficacy of antisense oligonucleotide therapy of novel PRPF3 intronic splice variant by Vadim Dolgin, Ekaterina Eremenko, Ginat Narkis, Masha Mazor-Oring, Libe Gradstein, Ohad S. Birk (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13213770.txt.

Description

Vadim Dolgin and co-authors report a 2026 study of a gene therapy test for an inherited eye disease. The team found a new gene change in a family where it passed down through four generations. The change sits in a gene called PRPF3 and breaks the normal cutting and joining of its message. They built a lab test with two glow signals to watch that cutting step. Normal genes glowed, while the changed gene did not.

Eight short therapy strands were then tried in cells with the changed gene. A delivery form based on a small natural RNA carried each strand into the cells. A sorting machine counted how many cells glowed again after each try. That let the team pick the strand that restored the normal pattern best. The method could speed therapy design for such gene changes.

Catalog record

CREATORVadim Dolgin, Ekaterina Eremenko, Ginat Narkis, Masha Mazor-Oring, Libe Gradstein, Ohad S. Birk
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13213770

Browse the full library · About the Tower of Babel